The Role of Pharmacogenomics in Postoperative Pain Management
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature..
Pharmacogenomics can improve pain management by considering individual variations in pain perception and susceptibility and sensitivity to medicines related to genetic diversity. Due to the subjective nature of pain and the fact that people respond differently to medicines, it can be challenging to develop a consistent and successful regimen for pain disorders. Numerous factors influence the outcome of pain treatment programs, but two stand out: altered perception of pain and varying responsiveness to analgesic medicines. Numerous polymorphisms in genes such as CYP2D6, OPRM1, and ABCB1 have been identified, culminating in a heterogeneous response to pain medication in people who have these genetic polymorphisms. Improved treatment regimens that factor in pharmacogenetic differences in patients would help reduce the risk of opioid dependency and help effectively treat postoperative pain.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2547 |
|---|---|
| Enthalten in: |
Methods in molecular biology (Clifton, N.J.) - 2547(2022) vom: 06., Seite 505-526 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sachtleben, E Paylor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute pain |
|---|
| Anmerkungen: |
Date Completed 08.09.2022 Date Revised 04.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-1-0716-2573-6_18 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345856155 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345856155 | ||
| 003 | DE-627 | ||
| 005 | 20231226030032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-1-0716-2573-6_18 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1152.xml |
| 035 | |a (DE-627)NLM345856155 | ||
| 035 | |a (NLM)36068475 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sachtleben, E Paylor |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Role of Pharmacogenomics in Postoperative Pain Management |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2022 | ||
| 500 | |a Date Revised 04.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Pharmacogenomics can improve pain management by considering individual variations in pain perception and susceptibility and sensitivity to medicines related to genetic diversity. Due to the subjective nature of pain and the fact that people respond differently to medicines, it can be challenging to develop a consistent and successful regimen for pain disorders. Numerous factors influence the outcome of pain treatment programs, but two stand out: altered perception of pain and varying responsiveness to analgesic medicines. Numerous polymorphisms in genes such as CYP2D6, OPRM1, and ABCB1 have been identified, culminating in a heterogeneous response to pain medication in people who have these genetic polymorphisms. Improved treatment regimens that factor in pharmacogenetic differences in patients would help reduce the risk of opioid dependency and help effectively treat postoperative pain | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute pain | |
| 650 | 4 | |a Chronic pain | |
| 650 | 4 | |a Pain management | |
| 650 | 4 | |a Pharmacogenetics | |
| 650 | 4 | |a Pharmacogenomics | |
| 650 | 4 | |a Postoperative pain | |
| 650 | 4 | |a Precision medicine | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 700 | 1 | |a Rooney, Kelsey |e verfasserin |4 aut | |
| 700 | 1 | |a Haddad, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Lassiegne, Victoria L |e verfasserin |4 aut | |
| 700 | 1 | |a Boudreaux, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Cornett, Elyse M |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Methods in molecular biology (Clifton, N.J.) |d 1984 |g 2547(2022) vom: 06., Seite 505-526 |w (DE-627)NLM074849794 |x 1940-6029 |7 nnns |
| 773 | 1 | 8 | |g volume:2547 |g year:2022 |g day:06 |g pages:505-526 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-0716-2573-6_18 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2547 |j 2022 |b 06 |h 505-526 | ||